Shilpa Medicare Ltd

- Shilpa Medicare is setting up a dedicated API manufacturing block funded by their client (Unicycive Therapeutics) with a capex of approximately $6.5 million. - This dedicated block is being created to ensure supply does not hamper existing deliveries and will be ready within the next year. - The client is fully funding this capex; Shilpa is not contributing to this investment. - The dedicated block will have capacity sufficient for supply requirements over the next 2-3 years. - The funding and dedicated capacity demonstrate the strategic importance of this product and project to Shilpa. - No additional strategic or capital investments were specifically mentioned beyond this API block’s capex during the call.

- The new API plant funded by the innovator will suffice supply for the next 2-3 years, indicating expected volume growth in that period. - Binding orders currently include 5 million tablets by June 2025 and 15 million by December 2025, with multi-million tablets expected annually thereafter. - Commercial supplies are set to start from Q1 2025, aligned with anticipated FDA approval within 10-12 months. - Revenue includes a $10 million cumulative licensing fee expected mostly before product approval, plus additional sales revenue post-launch. - EBITDA margin for this NCE molecule is expected above 50%, showing strong profitability prospects. - The four-year exclusive manufacturing agreement with potential renewal for an additional four years provides a multi-year revenue runway. - The product targets a phosphate binder market worth over $1 billion, with global expansion plans beyond the U.S. over time.

- Shilpa Medicare's collaboration on the Oxylanthanum Carbonate (OLC) NCE molecule with Unicycive is expected to be a substantial revenue generator, with multimillion-dollar potential. - The company expects over 50% EBITDA margins from this exclusive CDMO supply contract. - Binding supply agreements involve supply of 5 million tablets by June 2025 and 15 million by December 2025, extending multi-year commercial supplies likely increasing revenues over several years. - $10 million cumulative milestone payments are expected, mostly before NDA approval, followed by ongoing sales revenue post launch. - The agreement is for four years, with automatic renewal for four more years, indicating a long runway for revenue and profit growth. - Pricing details are confidential, but favorable NCE exclusivity (likely 10+ years) and global manufacturing rights are expected to help sustain earnings. - Dedicated API manufacturing capacity expansion funded by the innovator ($6.5 million capex) supports expected volume growth for 2-3 years.

- Unicycive has placed binding orders of 5 million tablets to be delivered before June 2025 and 15 million tablets before December 2025. - The binding agreement with Unicycive is for a term of four years, with multi-million tablet volumes expected each year beyond initial orders. - For tail supply, there is an order of 15 million tablets to be supplied before December. - The dedicated API manufacturing plant funded by Unicycive will suffice supply requirements for the next 2-3 years. - Currently, supply is ongoing from existing blocks while a dedicated manufacturing block is being built, expected to be ready in about one year. - There are no other near-commercialization projects besides OLC at present.

- There is no mention in the transcript about any current or future fundraising through debt or equity. - The discussion primarily focuses on the $6.5 million capex funding for the dedicated API block, which is entirely funded by the innovator (Unicycive) with no financial outlay from Shilpa Medicare. - No additional plans for capital raising through equity or debt are discussed during the call. - The company appears focused on executing the existing manufacturing and supply agreements, along with milestone and licensing revenue.